A novel injectable TLR7/8 dual agonist, 3 M-052, triggered innate immunity and activated systemic tumor-specific CD8+ T cell immunity, leading to the rejection of distant uninjected tumors without systemic cytokine release and toxicity [253]. Here, CD8A is linked to neoplasm.